Skip to main content
Search
Search
Advanced Search
Skip main navigation
Open access
Editorial
21 December 2022

Journal of Comparative Effectiveness Research welcoming the submission of study design protocols to foster transparency and trust in real-world evidence

Authors: Joanne Walker [email protected], Laura Dormer, and Phil GarnerAuthor Info & Affiliations
Volume 12, Number 1
https://doi.org/10.2217/cer-2022-0197
PDFFormats
First page of PDF

Formats available

You can view the full content in the following formats:

View PDFView Full Text

References

1.
Hopewell S, Boutron I, Chan AW et al. An update to SPIRIT and CONSORT reporting guidelines to enhance transparency in randomized trials. Nat. Med. 28(9), 1740–1743 (2022).
PubMed
Google Scholar
2.
Spahr A, Rosli Z, Legault M et al. The LORIS MyeliNeuroGene rare disease database for natural history studies and clinical trial readiness. Orphanet J. Rare Dis. 16(1), 328 (2021).
PubMed
Google Scholar
3.
US Food and Drug Administration. Rare diseases: natural history studies for drug development. www.fda.gov/regulatory-information/search-fda-guidance-documents/rare-diseases-natural-history-studies-drug-development
Google Scholar
4.
Wang SV, Pinheiro S, Hua W et al. STaRT-RWE: structured template for planning and reporting on the implementation of real world evidence studies. Brit. Med. J. 372, m4856 (2021).
PubMed
Google Scholar
6.
Wang SV, Pottegård A, Crown W et al. HARmonized Protocol template to enhance reproducibility of hypothesis evaluating real-world evidence studies on treatment effects: a Good Practices Report of a joint ISPE/ISPOR Task Force. Value Health 25(10), 1663–1672 (2022).
PubMed
Google Scholar
7.
Wang SV, Pinheiro S, Hua W et al. STaRT-RWE: structured template for planning and reporting on the implementation of real world evidence studies. Brit. Med. J. 372, m4856 (2021).
PubMed
Google Scholar
8.
Seewald MJ, Plumb JM, Gutierrez B et al. Strengthening pharma's contract with society: the value of trusted partnerships between pharma and healthcare facilitated by real-world data. J. Comp. Eff. Res. 9(3), 155–159 (2020).
PubMed
Google Scholar
9.
Orsini LS, Berger M, Crown W et al. Improving transparency to build trust in real-world secondary data studies for hypothesis testing – why, what, and how: recommendations and a road map from the Real-World Evidence Transparency Initiative. Value Health 23(9), 1128–1136 (2020).
PubMed
Google Scholar
|